Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Elraglusib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actuate Receives EMA Orphan Status For Elraglusib In Cancer
    Actuate Receives EMA Orphan Status For Elraglusib In Cancer

    07 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/07/3005368/0/en/Actuate-Therapeutics-Receives-EMA-Orphan-Medicinal-Product-Designation-for-Elraglusib-for-the-Treatment-of-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    07 Jan 2025
    Share Share
    Actuate Therapeutics Announces Interim Data for Elraglusib
    Actuate Therapeutics Announces Interim Data for Elraglusib

    17 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/17/2998254/0/en/Actuate-Therapeutics-Announces-Positive-Interim-Phase-2-Data-of-Elraglusib-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    17 Dec 2024
    Share Share
    Actuate Gets FDA Rare Pediatric Designation for Elraglusib
    Actuate Gets FDA Rare Pediatric Designation for Elraglusib

    12 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/12/2979076/0/en/Actuate-Announces-FDA-Rare-Pediatric-Disease-Designation-Granted-to-Elraglusib-for-Treatment-of-Ewing-Sarcoma.html

    GLOBENEWSWIRE
    12 Nov 2024
    Share Share
    Actuate Reports Elraglusib Mechanism In Scientific Reports
    Actuate Reports Elraglusib Mechanism In Scientific Reports

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/23/2951343/0/en/Actuate-Announces-Scientific-Reports-Publication-on-Elraglusib-s-Novel-Immunomodulatory-Mechanism-of-Action-as-a-GSK-3%CE%B2-Inhibitor.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    Actuate Announces Elraglusib Data Presentation At AACR
    Actuate Announces Elraglusib Data Presentation At AACR

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2946577/0/en/Actuate-Announces-Upcoming-Presentation-on-Initial-Data-on-Elraglusib-in-Combination-with-FOLFIRINOX-at-the-AACR-Special-Conference-on-Advances-in-Pancreatic-Cancer-Research.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    Actuate Gets FDA Orphan Drug Designation For Elraglusib In Sarcomas
    Actuate Gets FDA Orphan Drug Designation For Elraglusib In Sarcomas

    11 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/11/2944428/0/en/Actuate-Receives-FDA-Orphan-Drug-Designation-for-Elraglusib-for-Treatment-of-Soft-Tissue-Sarcomas.html

    GLOBENEWSWIRE
    11 Sep 2024
    Share Share